Harrison Ross - Dec 21, 2021 Form 3 Insider Report for MARIZYME INC (MRZM)

Role
Vice President of Finance
Signature
/s/ Harrison Ross
Stock symbol
MRZM
Transactions as of
Dec 21, 2021
Transactions value $
$0
Form type
3
Date filed
1/13/2022, 07:58 PM
Next filing
Mar 21, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding MRZM Common Stock 175K Dec 21, 2021 By Rydra Capital Corp. F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding MRZM Consultant Stock Option (Right to Buy) Dec 21, 2021 Common Stock 200K $1.75 By Rydra Capital Corp. F2
holding MRZM Warrants (Right to Buy) Dec 21, 2021 Common Stock 100K $1.26 By Rydra Capital Corp.
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted shares of common stock of the issuer (the "Restricted Shares"), subject to the following milestone vesting schedule: (a) 75,000 Restricted Shares will vest upon the issuer successfully listing its common stock on NASDAQ or the NYSE; 50,000 Restricted Shares will vest upon any issuer financing after January 1, 2022 of debt or equity in which the gross proceeds equal or exceed $5,000,000; (c) 25,000 Restricted Shares will vest upon the completion of valuation reports for both Somahlution LLC and Health Logic Interactive Inc.; and (d) 25,000 Restricted Shares will vest upon a material commercial partnership for the issuer's MATLOC product.
F2 Vests monthly over two years following the date of grant on December 21, 2021.